InMed Pharmaceuticals Inc (TSE:IN) Director Eric Ashley Adams acquired 100,000 shares of the firm’s stock in a transaction dated Thursday, November 28th. The stock was bought at an average price of C$0.25 per share, for a total transaction of C$25,000.00. Following the completion of the acquisition, the director now owns 530,725 shares in the company, valued at approximately C$132,681.25.
InMed Pharmaceuticals stock opened at C$0.25 on Wednesday. The company has a market capitalization of $42.21 million and a PE ratio of -3.01. The company has a debt-to-equity ratio of 3.36, a quick ratio of 10.09 and a current ratio of 10.30. InMed Pharmaceuticals Inc has a fifty-two week low of C$0.22 and a fifty-two week high of C$0.80. The firm has a 50 day moving average price of C$0.26 and a 200 day moving average price of C$0.32.
InMed Pharmaceuticals (TSE:IN) last released its quarterly earnings results on Friday, November 8th. The company reported C($0.02) EPS for the quarter, hitting analysts’ consensus estimates of C($0.02). As a group, equities research analysts forecast that InMed Pharmaceuticals Inc will post -0.1122449 earnings per share for the current year.
InMed Pharmaceuticals Inc, a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain.
Further Reading: Diversification Important in Investing
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.